Movement disorders in children and adolescents

Neurologic Clinics

Volumn 20, Issue 4, 2002, Pages 1101-1124

  McMahon, William M ^a,c   Filloux, Francis M ^b   Ashworth, James C ^b   Jensen, Jenise ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BACLOFEN; BOTULINUM TOXIN; CATAPRESS; CENTRAL STIMULANT AGENT; CLONIDINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; GUANFACINE; HALOPERIDOL; IMIPRAMINE; IMMUNOGLOBULIN; NEUROLEPTIC AGENT; PENICILLIN G; PERGOLIDE; PIMOZIDE; RESERPINE; RISPERIDONE; STEROID; TETRABENAZINE; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; ANHEDONIA; CHOREA MINOR; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG INDICATION; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HUMAN; INSOMNIA; IRRITABILITY; LETHARGY; LONG QT SYNDROME; MEDICAL DECISION MAKING; MOTOR DYSFUNCTION; NAUSEA; NEUROLOGIC EXAMINATION; ORTHOSTATIC HYPOTENSION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC FEVER; SEDATION; SEX RATIO; SIDE EFFECT; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; TREATMENT PLANNING; TREMOR; VERTIGO; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHOREATIC DISORDERS; HUMANS; MOVEMENT DISORDERS; STREPTOCOCCAL INFECTIONS; TICS; TOURETTE SYNDROME;

EID: 0036830332     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(02)00015-4     Document Type: Review

References (177)

1. Robertson MM, Eapen V, editors. Movement and Allied Disorders in Childhood. Chichester: John Wiley & Sons Ltd; 1995.
2. Saunders-Pullman R, Braun I, Bressman S. Pediatric movement disorders. Child Adolesc Psychiatr Clin North Am 1999;8:747-65.
3. Goetz CG, Klawans HL. Gilles de la Tourette on Tourette syndrome. Adv Neurol 1982;35:1-16.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Text Revision. Washington, DC: American Psychiatric Association; 2000.
5. The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol 1993;50:1013-6.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association; 1994.
7. Scahill L, Tanner C, Dure L. The epidemiology of tics and Tourette syndrome in children and adolescents. Adv Neurol 2001;85:261-71.
8. Comings DE, Himes JA, Comings BG. An epidemiologic study of Tourette's syndrome in a single school district. J Clin Psychiatry 1990;51:463-9.
9. Apter A, Pauls DL, Bleich A, et al. An epidemiologic study of Gilles de la Tourette's syndrome in Israel. Arch Gen Psychiatry 1993;50:734-8.
10. Costello EJ, Angold A, Burns BJ, et al. The Great Smoky Mountains study of youth, goals, design, and the prevalence of DSM-III-R disorders. Arch Gen Psychiatry 1996;53:129-36.
11. Burd L, Kerbeshian J, Wikenheiser M, et al. A prevalence study of Gilles de la Tourette syndrome in North Dakota school-age children. J Am Acad Child Psychiatry 1986;25:552-3.
12. Goetz CG, Tanner CM, Stebbins GT, et al. Adult tics in Gilles de la Tourette's syndrome: Description and risk factors. Neurology 1992;42:784-8.
13. Leckman JF, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: The first two decades. Pediatrics 1998;102:14-9.
14. Peterson BS, Leckman JF. The temporal dynamics of tics in Gilles de la Tourette syndrome. Biol Psychiatry 1998;44:1337-48.
15. Jankovic J. Tourette's syndrome. N Engl J Med 2001;345:1184-92.
16. Merette C, Brassard A, Potvin A, et al. Significant linkage for Tourette syndrome in a large French Canadian family. Am J Hum Genet 2000;67:1008-13.
17. The Tourette Syndrome Association International Consortium for Genetics. A complete genome screen in sib pairs affected by Gilles de la Tourette Syndrome. Am J Hum Genet 1999;65:1428-36.
18. Zhang H, Leckman JF, Pauls DL, et al. Genome wide scan of hoarding in sibling pairs both diagnosed with Gilles de la Tourette syndrome. Am J Hum Genet 2002;70:896-904.
19. Leckman JF, Peterson BS, Anderson GM, et al. Pathogenesis of Tourette's syndrome. J Child Psychol Psychiatry 1997;38:119-42.
20. Leckman JF, Riddle MA. Tourette's syndrome: When habit-forming systems form habits of their own? Neuron 2000;28:349-54.
21. Anderson GM, Pollak ES, Chatterjee D, et al. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv Neurol 1992;58:123-33.
22. Haber SN, Kowall NW, Vonsattel JP, et al. Gilles de la Tourette's syndrome. A postmortem neuropathological and immunohistochemical study. J Neurol Sci 1986;75:225-41.
23. Haber SN, Wolfer D. Basal ganglia peptidergic staining in Tourette syndrome. A follow-up study. Adv Neurol 1992;58:145-50.
24. Singer HS. Neurochemical analysis of postmortem cortical and striatal brain tissue in patients with Tourette syndrome. Adv Neurol 1992;58:135-44.
25. Peterson BS. Neuroimaging studies of Tourette syndrome: A decade of progress. Adv Neurol 2001;85:179-96.
26. Peterson BS, Staib L, Scahill L, et al. Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry 2001;58:427-40.
27. Fredericksen KA, Cutting LE, Kates WR, et al. Disproportionate increases of white matter in right frontal lobe in Tourette syndrome. Neurology 2002;58:85-9.
28. Biswal B, Ulmer JL, Krippendorf RL, et al. Abnormal cerebral activation associated with a motor task in Tourette syndrome. AJNR Am J Neuroradiol 1998;19:1509-12.
29. Braun AR, Stoetter B, Randolph C, et al. The functional neuroanatomy of Tourette's syndrome: An FDG-PET studyI. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology 1993;9:277-91.
30. Chase TN, Geoffrey V, Gillespie M, et al. Structural and functional studies of Gilles de la Tourette syndrome. Rev Neurol (Paris) 1986;142:851-5.
31. Hall M, Costa DC, Shields J, et al. Brain perfusion patterns with Tc-99m-HMPAO/SPET in patients with Gilles de la Tourette syndrome. Eur J Nucl Med 1990;16:564(WP18).
32. Moriarty J, Costa DC, Schmitz B, et al. Brain perfusion abnormalities in Gilles de la Tourette's syndrome. Br J Psychiatry 1995;167:249-54.
33. Peterson BS, Skudlarski P, Anderson AW, et al. A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Arch Gen Psychiatry 1998;55:326-33.
34. Riddle MA, Rasmusson AM, Woods SW, et al. SPECT imaging of cerebral blood flow in Tourette syndrome. Adv Neurol 1992;58:207-11.
35. Peterson BS, Skudlarski P, Gatenby JC, et al. An fMRI study of Stroop word-color interference: Evidence for cingulate subregions subserving multiple distributed attentional systems. Biol Psychiatry 1999;45:1237-58.
36. Ernst M, Zametkin AJ, Jons PH, et al. High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1999;38:86-94.
37. Heinz A, Knable MB, Wolf SS, et al. Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology 1998;51:1069-74.
38. Malison RT, McDougle CJ, van Dyck CH, et al. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-61.
39. Wolf SS, Jones DW, Knable MB, et al. Tourette syndrome: Prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 1996;273:1225-7.
40. Mostofsky SH, Wendlandt J, Cutting L, et al. Corpus callosum measurements in girls with Tourette syndrome. Neurology 1999;53:1345-7.
41. Zimmerman AM, Abrams MT, Giuliano JD, et al. Subcortical volumes in girls with Tourette syndrome: Support for a gender effect. Neurology 2000;54:2224-9.
42. Durston S, Hulshoff Pol HE, Casey BJ, et al. Anatomical MRI of the developing human brain: What have we learned? J Am Acad Child Adolesc Psychiatry 2001;40:1012-20.
43. Giedd JN, Castellanos FX, Rajapakse JC, et al. Sexual dimorphism of the developing human brain. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:1185-201.
44. Giedd JN, Rumsey JM, Castellanos FX, et al. A quantitative MRI study of the corpus callosum in children and adolescents. Brain Res Dev Brain Res 1996;91:274-80.
45. Giedd JN, Vaituzis AC, Hamburger SD, et al. Quantitative MRI of the temporal lobe, amygdala, and hippocampus in normal human development: Ages 4-18 years. J Comp Neurol 1996;366:223-30.
46. Lange N, Giedd JN, Castellanos FX, et al. Variability of human brain structure size: Ages 4-20 years. Psychiatry Res 1997;74:1-12.
47. Reiss AL, Abrams MT, Singer HS, et al. Brain development, gender and IQ in children. A volumetric imaging study. Brain 1996;119:1763-74.
48. Sheppard DM, Bradshaw JL, Purcell R, et al. Tourette's and comorbid syndromes: Obsessive compulsive and attention deficit hyperactivity disorder. A common etiology? Clin Psychol Rev 1999;19:531-52.
49. Walkup JT, Khan S, Schuerholz L, et al. Phenomenology and natural history of ticrelated ADHD and learning disabilities. In: Leckman JF, Cohen DJ, editors. Tourette's Syndrome - Tics, Obsessions, Compulsions. Developmental Psychopathology and Clinical Care. New York: John Wiley & Sons Ltd; 1999. p. 63-79.
50. Caprini G, Melotti V. Un grave sindrome ticcosa guarita con haloperidol. Rivista Sperimentale di Freniatria e Medicina Legalle Delle Alienzioni Mentali 1961;85:191-6.
51. Challas G, Brauer W. Tourette's disease: Relief of symptoms with R 1625. Am J Psychiatry 1963;120:283-4.
52. Seignot MJN. Un cas de maladie des tics de Gilles de la Tourette gueri par le R-1625. Annales Medico-Psychologiques 1961;119:578-9.
53. Shapiro AK, Shapiro E. Treatment of Gilles de la Tourette's syndrome with haloperidol. Br J Psychiatry 1968;114:345-50.
54. Shapiro AK, Shapiro ES, Bruun RD, et al. History of tics and Tourette syndrome. In: Gilles de la Tourette Syndrome. New York: Raven Press; 1978. p. 11-82.
55. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997;154:1057-62.
56. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;46:722-30.
57. Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders. Arch Neurol 1984;41:271-2.
58. Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136:317-20.
59. Rabinowitz J, Hornik T, Davidson M. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry 2001;62:343-6.
60. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067-74.
61. Gilbert DL, Sethuraman G, Sine L, et al. Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000;54:1310-5.
62. Marras C, Andrews D, Sime E, et al. Botulinum toxin for simple motor tics: A randomized, double-blind, controlled clinical trial. Neurology 2001;56:605-10.
63. Awaad Y. Tics in Tourette syndrome: New treatment options. J Child Neurol 1999;14:316-9.
64. Singer HS, Wendlandt J, Krieger M, et al. Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial. Neurology 2001;56:599-604.
65. Walter AL, Carter AS. Gilles de la Tourette's syndrome in childhood: A guide for school professionals. School Psychology Rev 1997;26:28-46.
66. Dilenge ME, Shevell MI, Dinh L. Restricted unilateral Sydenham's chorea: Reversible contralateral striatal hypermetabolism demonstrated on single photon emission computed tomographic scanning. J Child Neurol 1999;14:509-13.
67. Garvey MA, Swedo SE. Sydenham's chorea. Clinical and therapeutic update. Adv Exp Med Biol 1997;418:115-20.
68. Goldenberg J, Ferraz MB, Fonseca AS, et al. Sydenham chorea: Clinical and laboratory findings. Analysis of 187 cases. Rev Paul Med 1992;110:152-7.
69. Heye N, Jergas M, Hotzinger H, et al. Sydenham chorea: Clinical, EEG, MRI and SPECT findings in the early stage of the disease. J Neurol 1993;240:121-3.
70. Swedo SE, Leonard HL, Schapiro MB, et al. Sydenham's chorea: Physical and psychological symptoms of St. Vitus dance. Pediatrics 1993;91:706-13.
71. Van der Merwe PL, Kalis NN. Sydenham's chorea - Analysis of 27 patients and a review of the literature. S Afr Med J 1997;87(Suppl 3):C157-60.
72. Wilcox JA, Nasrallah H. Sydenham's chorea and psychopathology. Neuropsychobiology 1988;19:6-8.
73. Swedo SE, Rapoport JL, Cheslow DL, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry 1989;146:246-9.
74. Mercadante MT, Busatto GF, Lombroso PJ, et al. The psychiatric symptoms of rheumatic fever. Am J Psychiatry 2000;157:2036-8.
75. Berrios X, Quesney F, Morales A, et al. Are all recurrences of "pure" Sydenham chorea true recurrences of acute rheumatic fever? J Pediatr 1985;107:867-72.
76. Gibb WR, Lees AJ, Scadding JW. Persistent rheumatic chorea. Neurology 1985;35:101-2.
77. Abraham S, O'Gorman M, Shulman ST. Anti-nuclear antibodies in Sydenham's chorea. Adv Exp Med Biol 1997;418:153-6.
78. Figueroa F, Berrios X, Gutierrez M, et al. Anticardiolipin antibodies in acute rheumatic fever [see comments]. J Rheumatol 1992;19:1175-80.
79. Mirkinson L. The diagnosis of rheumatic fever. Pediatr Rev 1998;19:310-1.
80. Persellin RH. Acute rheumatic fever: Changing manifestations. Ann Intern Med 1978;89:1002-3.
81. Bisno AL. The resurgence of acute rheumatic fever in the United States. Annu Rev Med 1990;41:319-29.
82. Veasy LG, Tani LY, Hill HR. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr 1994;124:9-16.
83. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987;316:421-7.
84. Kaplan EL, Rothermel CD, Johnson DR. Antistreptolysin O and anti-deoxyribonuclease B titers: Normal values for children ages 2 to 12 in the United States. Pediatrics 1998;101:86-8.
85. Abernethy M, Bass N, Sharpe N, et al. Doppler echocardiography and the early diagnosis of carditis in acute rheumatic fever. Aust NZ J Med 1994;24:530-5.
86. Davies C, Sahn D. Detection and significance of subclinical mitral regurgitation by colour Doppler techniques [letter, comment]. Heart 2001;85:369-70.
87. Elevli M, Celebi A, Tombul T, et al. Cardiac involvement in Sydenham's chorea: Clinical and Doppler echocardiographic findings. Acta Paediatr 1999;88:1074-7.
88. Figueroa FE, Fernandez MS, Valdes P, et al. Prospective comparison of clinical and echocardiographic diagnosis of rheumatic carditis: Long term follow up of patients with subclinical disease [see comments]. Heart 2001;85:407-10.
89. Folger GM, Hajar R, Robida A, et al. Occurrence of valvar heart disease in acute rheumatic fever without evident carditis: Colour-flow Doppler identification. Br Heart J 1992;67:434-8.
90. Ozkutlu S, Ayabakan C, Saraclar M. Can subclinical valvitis detected by echocardiography be accepted as evidence of carditis in the diagnosis of acute rheumatic fever? Cardiology in the Young 2001;11:255-60.
91. Minich LL, Tani LY, Pagotto LT, et al. Doppler echocardiography distinguishes between physiologic and pathologic "silent" mitral regurgitation in patients with rheumatic fever. Clin Cardiol 1997;20:924-6.
92. al Jishi F, al Kawi MZ, el Ramahi K, et al. Hemichorea in systemic lupus erythematosus: Significance of MRI findings. Lupus 1995;4:321-3.
93. Besbas N, Damarguc I, Ozen S, et al. Association of antiphospholipid antibodies with systemic lupus erythematosus in a child presenting with chorea: A case report [see comments]. Eur J Pediatr 1994;153:891-3.
94. Font J, Cervera R, Espinosa G, et al. Systemic lupus erythematosus (SLE) in childhood: Analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998;57:456-9.
95. Angelini L, Zibordi F, Zorzi G, et al. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. Neuropediatrics 1996;27:149-53.
96. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997;76:203-12.
97. Kiechl-Kohlendorfer U, Ellemunter H, Kiechl S. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics 1999;30:96-8.
98. Levine SR, Brey RL. Neurological aspects of antiphospholipid antibody syndrome. Lupus 1996;5:347-53.
99. Masala C, Morino S, Zangari P, et al. Chorea in primary antiphospholipid syndrome. Clin Neurol Neurosurg 1996;98:247-8.
100. Okseter K, Sirnes K. Chorea and lupus anticoagulant: A case report. Acta Neurol Scand 1988;78:206-9.
101. Dale RC, Church AJ, Cardoso F, et al. Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol 2001;50:588-95.
102. Fujinami RS, Oldstone MB. Molecular mimicry as a mechanism for virus-induced autoimmunity. Immunol Res 1989;8:3-15.
103. Husby G, v de Rijn I, Zabriskie JB, et al. Anti-neuronal antibody in Sydenham's chorea. Lancet 1977;1:1208.
104. Dorling J, Kingston D, Webb JA. Anti-streptococcal antibodies reacting with brain tissue. II. Utrastructural studies. Br J Exp Pathol 1976;57:255-65.
105. Husby G, Forre O, Williams RC Jr. IgG subclass, variable H-chain subgroup, and light chain-type composition of antineuronal antibody in Huntington's disease and Sydenham's chorea. Clin Immunol Immunopathol 1979;14:361-7.
106. Kingston D, Glynn LE. Anti-streptococcal antibodies reacting with brain tissue. I. Immunofluorescent studies. Br J Exp Pathol 1976;57:114-28.
107. Swedo SE. Sydenham's chorea. A model for childhood autoimmune neuropsychiatric disorders. JAMA 1994;272:1788-91.
108. Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol 1993;151:2820-8.
109. Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies in movement disorders. Pediatrics 1993;92:39-43.
110. Morshed SA, Parveen S, Leckman JF, et al. Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette's syndrome, Sydenham's chorea, and autoimmune disorders. Biol Psychiatry 2001;50:566-77.
111. Arnold PD, Richter MA. Is obsessive-compulsive disorder an autoimmune disease? CMAJ 2001;165:1353-8.
112. Murphy TK, Petitto JM, Voeller KK, et al. Obsessive compulsive disorder: Is there an association with childhood streptococcal infections and altered immune function? Semin Clin Neuropsychiatry 2001;6:266-76.
113. Swedo SE, Leonard HL. Childhood movement disorders and obsessive compulsive disorder. J Clin Psychiatry 1994;55(Suppl):32-7.
114. Singer HS, Giuliano JD, Hansen BH, et al. Antibodies against a neuron-like (HTB-10 neuroblastoma) cell in children with Tourette syndrome. Biol Psychiatry 1999;46:775-80.
115. Singer HS, Giuliano JD, Hansen BH, et al. Antibodies against human putamen in children with Tourette syndrome. Neurology 1998;50:1618-24.
116. Visvanathan K, Trifiletti RR, Altemus M, et al. Autoimmune mechanisms in movement disorders. Semin Pediatr Neurol 2000;7:103-7.
117. Castillo M, Kwock L, Arbelaez A. Sydenham's chorea: MRI and proton spectroscopy. Neuroradiology 1999;41:943-5.
118. Emery ES, Vieco PT. Sydenham chorea: Magnetic resonance imaging reveals permanent basal ganglia injury. Neurology 1997;48:531-3.
119. Hill A, Herkes GK, Roche P. SPECT and MRI findings in Sydenham's chorea. J Neurol Neurosurg Psychiatry 1994;57:763.
120. Ikuta N, Hirata M, Sasabe F, et al. High-signal basal ganglia on T1-weighted images in a patient with Sydenham's chorea. Neuroradiology 1998;40:659-61.
121. Ju TH, Kao KP, Chen CC. Sydenham chorea. AJNR Am J Neuroradiol 1993;14:1265.
122. Traill Z, Pike M, Byrne J. Sydenham's chorea: A case showing reversible striatal abnormalities on CT and, MRI. Dev Med Child Neurol 1995;37:270-3.
123. Giedd JN, Rapoport JL, Kruesi MJ, et al. Sydenham's chorea: Magnetic resonance imaging of the basal ganglia. Neurology 1995;45:2199-202.
124. Giedd JN, Rapoport JL, Garvey MA, et al. MRI assessment of children with obsessivecompulsive disorder or tics associated with streptococcal infection. Am J Psychiatry 2000;157:281-3.
125. Giedd JN, Rapoport JL, Leonard HL, et al. Case study: Acute basal ganglia enlargement and obsessive-compulsive symptoms in an adolescent boy. J Am Acad Child Adolesc Psychiatry 1996;35:913-5.
126. Singer HS, Reiss AL, Brown JE, et al. Volumetric MRI changes in basal ganglia of children with Tourette's syndrome. Neurology 1993;43:950-6.
127. Goldman S, Amrom D, Szliwowski HB, et al. Reversible striatal hypermetabolism in a case of Sydenham's chorea. Mov Disord 1993;8:355-8.
128. Lee PH, Nam HS, Lee KY, et al. Serial brain SPECT images in a case of Sydenham chorea. Arch Neurol 1999;56:237-40.
129. Weindl A, Kuwert T, Leenders KL, et al. Increased striatal glucose consumption in Sydenham's chorea. Mov Disord 1993;8:437-44.
130. Garvey MA, Swedo SE, Shapiro MB, et al. Intravenous immunoglobulin and plasmapheresis treatments of Sydenham's chorea [abstract]. Neurology 1996;46:A147.
131. Lue HC, Wu MH, Hsieh KH, et al. Rheumatic fever recurrences: Controlled study of 3-week versus 4-week benzathine penicillin prevention programs. J Pediatr 1986;108:299-304.
132. American Academy of Pediatrics. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th Edition. Elk Grove Village, IL: American Academy of Pediatrics; 2000.
133. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999;354:1153-8.
134. Thompson JA, Tani LY, Bale JF. Sydenham chorea: The Utah experience. Ann Neurol 1999;46:523 (Abstract).
135. Allen AJ, Leonard HL, Swedo SE. Case study: A new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1995;34:307-11.
136. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: Clinical description of the first 50 cases. Am J Psychiatry 1998;155:264-71.
137. Swedo SE, Leonard HL, Mittleman BB, et al. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry 1997;154:110-2.
138. Bessen DE, Lombroso PJ. Group A streptococcal infections and their potential role in neuropsychiatric disease. Adv Neurol 2001;85:295-305.
139. Hamilton CS, Garvey MA, Swedo SE. Therapeutic implications of immunology for tics and obsessive-compulsive disorder. Adv Neurol 2001;85:311-8.
140. Kurlan R. Could Tourette syndrome be a neurologic manifestation of rheumatic fever? Adv Neurol 2001;85:307-10.
141. Murphy TK, Goodman WK, Ayoub EM, et al. On defining Sydenham's chorea: Where do we draw the line? Biol Psychiatry 2000;47:851-7.
142. Murphy T, Goodman W. Genetics of childhood disorders: XXXIV. Autoimmune disorders, part 7: D8/17 reactivity as an immunological marker of susceptibility to neuropsychiatric disorders. J Am Acad Child Adolesc Psychiatry 2002;41:98-100.
143. Chapman F, Visvanathan K, Carreno-Manjarrez R, et al. A flow cytometric assay for D8/17 B cell marker in patients with Tourette's syndrome and obsessive compulsive disorder. J Immunol Methods 1998;219:181-6.
144. Khanna AK, Buskirk DR, Williams RC, Jr, et al. Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. J Clin Invest 1989;83:1710-6.
145. Regelmann WE, Talbot R, Cairns L, et al. Distribution of cells bearing "rheumatic" antigens in peripheral blood of patients with rheumatic fever/rheumatic heart disease. J Rheumatol 1989;16:931-5.
146. Murphy TK, Goodman WK, Fudge MW, et al. B lymphocyte antigen D8/17: A peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Am J Psychiatry 1997;154:402-7.
147. Lougee L, Perlmutter SJ, Nicolson R, et al. Psychiatric disorders in first-degree relatives of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). J Am Acad Child Adolesc Psychiatry 2000;39:1120-6.
148. Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies: Tics and obsessivecompulsive symptoms. J Dev Behav Pediatr 1994;15:421-5.
149. Muller N, Riedel M, Forderreuther S, et al. Tourette's syndrome and mycoplasma pneumoniae infection. Am J Psychiatry 2000;157:481-2.
150. Tucker DM, Leckman JF, Scahill L, et al. A putative poststreptococcal case of OCD with chronic tic disorder, not otherwise specified. J Am Acad Child Adolesc Psychiatry 1996;35:1684-91.
151. Peterson BS, Leckman JF, Tucker D, et al. Preliminary findings of antistreptococcal antibody titers and basal ganglia volumes in tic, obsessive-compulsive, and attention deficit/hyperactivity disorders. Arch Gen Psychiatry 2000;57:364-72.
152. Garvey MA, Giedd J, Swedo SE. PANDAS: The search for environmental triggers of pediatric neuropsychiatric disorders. Lessons from rheumatic fever. J Child Neurol 1998;13:413-23.
153. Hallett JJ, Harling-Berg CJ, Knopf PM, et al. Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction. J Neuroimmunol 2000;111:195-202.
154. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: Effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997;36:589-96.
155. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 1999;56:330-6.
156. Peterson BS, Leckman JF, Lombroso P, et al. Environmental risk and protective factors. In: Leckman JF, Cohen DJ, editors. Tourette's Syndrome - Tics, Obsessions, Compulsions. Developmental Psychopathology and Clinical Care. New York: John Wiley & Sons Ltd; 1999. p. 213-29.
157. Cunningham-Owens DG. Drug-related movement disorders. In: Robertson MM, Eapen V, editors. Movement and Allied Disorders in Childhood. Chichester: John Wiley & Sons Ltd; 2001, p. 199-236.
158. Basile VS, Masellis M, Badri F, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999;21:17-27.
159. Liao DL, Yeh YC, Chen HM, et al. Association between the SergGly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001;44:95-8.
160. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacologia 2000;152:408-13.
161. Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: New indications and new populations. J Psychiatr Res 2001;35:187-91.
162. McDermid SA, Hood J, Bockus S, et al. Adolescents on neuroleptic medication: Is this population at risk for tardive dyskinesia? Can J Psychiatry 1998;43:629-31.
163. Richardson MA, Haugland G, Craig TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 1991;148:1322-8.
164. Shay J, Sanchez LE, Cueva JE, et al. Neuroleptic-related dyskinesias and stereotypies in autistic children: Videotaped ratings. Psychopharmacol Bull 1993;29:359-63.
165. Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-43.
166. Kumra S, Jacobsen LK, Lenane M, et al. Case series: Spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998;37:221-7.
167. Silverstein FS, Johnston MV. Risks of neuroleptic drugs in children. J Child Neurol 1987;2:41-3.
168. Muscettola G, Barbato G, Pampallona S, et al. Extrapyramidal syndromes in neuroleptic-treated patients: Prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999;19:203-8.
169. Fenton WS, Blyler CR, Wyatt RJ, et al. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 1997;171:265-8.
170. Golden GS. Tardive dyskinesia in Tourette syndrome. Pediatr Neurol 1985;1:192-4.
171. Mizrahi EM, Holtzman D, Tharp B. Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease. Arch Neurol 1980;37:780.
172. Regeur L, Pakkenberg B, Fog R, et al. Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. J Neurol Neurosurg Psychiatry 1986;49:791-5.
173. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry 1988;145:621-4.
174. Fleischhacker WW, Lemmens P, van Baelen B. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. Pharmacopsychiatry 2001;34:104-10.
175. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 2000;39:292-9.
176. Carroll NB, Boehm KE, Strickland RT. Chorea and tardive dyskinesia in a patient taking risperidone. J Clin Psychiatry 1999;60:485-7.
177. Feeney DJ, Klykylo W. Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry 1996;35:1421-2.